Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCLMichael Northend, William Townsend, Andrew Davies et al.|Blood Advances|2022Cited by 44
A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCLGraham P. Collins, Dima El‐Sharkawi, William Townsend et al.|Blood|2023Cited by 9